Development and economic trends in cancer therapeutic drugs: A 5-year update 2010-2014

British Journal of Cancer

Volumn 112, Issue 6, 2015, Pages 1037-1041

  Savage, P ^a   Mahmoud, S ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

costs; developments; Drugs; economics

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKINE; CYTOTOXIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; PEPTIDE; PHOSPHOTRANSFERASE INHIBITOR; THALIDOMIDE;

ARTICLE; DRUG COST; DRUG INDICATION; GROSS NATIONAL PRODUCT; HEALTH CARE DELIVERY; PRIORITY JOURNAL; TREATMENT DURATION; UNITED KINGDOM; COST BENEFIT ANALYSIS; ECONOMICS; GREAT BRITAIN; HUMAN; NEOPLASMS; TRENDS;

ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; DRUG COSTS; GREAT BRITAIN; HUMANS; NEOPLASMS;

EID: 84925298403     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.56     Document Type: Article

References (15)

1. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235-242.
2. Experts in Chronic Myeloid Leukemia (2013) The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood 121: 4439-4442.
3. Fojo T, Mailankody S, Lo A (2014) Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley lecture. JAMA Otolaryngol Head Neck Surg 140: 1225-1236.
4. Kantarjian HM, Fojo T, Mathisen M, Zwelling LA (2013) Cancer drugs in the United States: Justum Pretium-the just price. J Clin Oncol 31: 3600-3604.
5. Khera N (2014) Reporting and Grading Financial Toxicity. J Clin Oncol 29: 3337-3338.
6. Light DW, Kantarjian H (2013) Market spiral pricing of cancer drugs. Cancer 119: 3900-3902.
7. Meropol NJ, Schrag D, Smith TJ, Mulvey TM, Langdon Jr RM, Blum D, Ubel PA, Schnipper LE,. American Society of Clinical Oncology (2009) American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol 27: 3868-3874.
8. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA (2009) Overall survival and updated results for sunitinib compared with interferon Alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 27: 3584-3590.
9. Niraula S, Amir E, Vera-Badillo F, Seruga B, Ocana A, Tannock IF (2014) Risk of incremental toxicities and associated costs of new anticancer drugs: a meta-analysis. J Clin Oncol 32: 3634-3642.
10. Office of National Statistics (2014) Accessed via http://www.theguardian.com/ news/datablog/2009/nov/25/gdp-uk-1948-growth-economy#data.
11. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, ODay SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ (2014) Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol 32: 129-160.
12. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Bladé J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC (2005) Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498.
13. Savage P (2012) Development and economic trends in cancer therapeutic drugs in the UK from 1955 to 2009. J Oncol Pharm Pract 18: 52-56.
14. de Souza JA, Yap BJ, Hlubocky FJ, Wroblewski K, Ratain MJ, Cella D, Daugherty CK (2014) The development of a financial toxicity patientreported outcome in cancer: The COST measure. Cancer 120: 3245-3253.
15. Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol NJ, Amir E, Khayat D, Boyle P, Autier P, Tannock IF, Fojo T, Siderov J, Williamson S, Camporesi S, McVie JG, Purushotham AD, Naredi P, Eggermont A, Brennan MF, Steinberg ML, De Ridder M, McCloskey SA, Verellen D, Roberts T, Storme G, Hicks RJ, Ell PJ, Hirsch BR, Carbone DP, Schulman KA, Catchpole P, Taylor D, Geissler J, Brinker NG, Meltzer D, Kerr D, Aapro M (2011) Delivering affordable cancer care in high-income countries. Lancet Oncol 12: 933-980.